Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Update: 2025-08-07

Description

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.

Comments

In Channel

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

2025-10-0918:31

Author Interview: Doctor David Kellner, September 2025

2025-10-0222:44

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

2025-09-2508:44

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

2025-09-1820:52

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

2025-09-0407:41

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

2025-08-2828:57

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

2025-08-1445:23

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

2025-08-0717:45

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

2025-07-3113:24

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

2025-07-1016:44

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

2025-07-0341:27

EULAR 2025 Review Podcast

2025-07-0201:05:19

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

2025-06-2615:20

EULAR 2025 Highlights: Day 4

2025-06-1403:25

EULAR 2025 Highlights: Day 3

2025-06-1302:36

Discussing PsA: Real-world data on biologic switching and the development of EMMs

2025-06-1223:11

EULAR 2025 Highlights: Day 2

2025-06-1204:39

EULAR 2025 Highlights: Day 1

2025-06-1104:03

EULAR 2025 Preview Podcast

2025-06-0925:23

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

2025-06-0510:25

00:00

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

The Immune-Mediated Inflammatory Disease Forum

#box-pro-ellipsis-17607896027155{-webkit-line-clamp:2;}Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

The Immune-Mediated Inflammatory Disease Forum

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials